NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xeltis

Xeltis

Private
EindhovenHealthcare & Life Scienceshttps://xeltis.com/

Last Round

Early Funding

Jul 28, 2026

Total Funding Raised

$223.02M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Xeltis is a medical device company that develops bioabsorbable heart valves and blood vessels aimed at promoting natural tissue restoration in cardiovascular therapy.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

endogenous tissue restorationETRregenerative medicinecardiovascular implantsbio-absorbable implantsvascular access graftheart valve replacementbiomaterialstissue engineeringhemodialysis accessmedical devicebio-scaffoldclinical-stage medtechvascular surgerymedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xeltis Comparables

Compare Xeltis with similar companies based on industry and business-model similarity.

Xeltis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PECA Labs, Inc.
85%
CorMatrix Cardiovascular, Inc.
81%
VeriGraft
81%

Xeltis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 28, 2026
VC RoundDec 2, 2025
DebtDec 2, 2025
Corporate FundingApr 8, 2025
Series D ExtensionAug 15, 2023
Series D
Feb 21, 2023

Key People

Founding team and executive leadership

Alexander Goemans

CFO

Executive Team

Xeltis Investors

Notable investors and investment history

Xeltis investors
InvestorRounds
European Innovation Council FundSeries D Extension, VC Round, Corporate Funding
EQT Life SciencesSeries C, Early Funding, Series D Extension, VC Round, Series D, Series B Extension, Series B
Invest-NLEarly Funding, Series D Extension, VC Round, Series D
Ysios CapitalSeries C, Series D
Horizon 3 HealthcareEarly Funding
VI PartnersSeries C, Early Funding, Series D, Series B Extension, Series B
European Investment Bank GroupDebt, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    CMO interviewed at LSX World Congress in Lisbon.

  • Dec 2, 2025

    $58.1M raised in a VC round.

Xeltis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xeltis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xeltis's valuation, stock price, and market status.

Firmographic Details

HeadquartersEindhoven
Employee Range85
Year Founded2006
Last FundingJul 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.